Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib

被引:5
|
作者
Fujiki, Toshihiro [1 ]
Sakai, Yuta [1 ]
Ikawa, Yasuhiro [1 ,3 ]
Takenaka, Mika [1 ]
Noguchi, Kazuhiro [1 ]
Kuroda, Rie [1 ]
Abe, Takatoshi [2 ]
Nomura, Kozo [2 ]
Sakai, Seisho [2 ]
Wada, Taizo [1 ]
机构
[1] Kanazawa Univ, Dept Pediat, Kanazawa, Ishikawa, Japan
[2] Kanazawa Univ, Dept Pediat Surg, Kanazawa, Ishikawa, Japan
[3] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Sch Med, Dept Pediat, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
基金
日本学术振兴会;
关键词
alectinib; ALK-FN1; ALK inhibitors; bladder; child; inflammatory myofibroblastic tumor; LARGE-CELL LYMPHOMA; URINARY-BLADDER; ALK; CRIZOTINIB;
D O I
10.1002/pbc.30172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm characterized by the proliferation of myofibroblasts and inflammatory cell infiltration. Although radical resection is the only established treatment strategy for IMT, it can cause functional disorders when vital organs are affected. We describe a case of pediatric IMT of the bladder with FN1-ALK (fibronectin 1-anaplastic lymphoma kinase) fusion. Radical resection might lead to urinary disturbance due to the large tumor size at diagnosis. However, the tumor was successfully treated with alectinib, a second-generation ALK inhibitor, followed by transurethral resection of the bladder tumor without any complications.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Inflammatory myofibroblastic tumor successfully treated with metformin: A case report and review of literature
    Liang, Yu
    Gao, Hong-Xiang
    Tian, Rui-Cheng
    Wang, Jing
    Shan, Yu-Hua
    Zhang, Lei
    Xie, Chen-Jie
    Li, Jing-Jing
    Xu, Min
    Gu, Song
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (02) : 429 - 435
  • [32] Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report
    Tateishi, Yoko
    Okudela, Koji
    Kawai, Shigeo
    Suzuki, Takehisa
    Umeda, Shigeaki
    Matsumura, Mai
    Kioi, Mitomu
    Ohashi, Kenichi
    DIAGNOSTIC PATHOLOGY, 2016, 11
  • [33] Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1-ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification
    Takeuchi, Kengo
    Soda, Manabu
    Togashi, Yuki
    Sugawara, Emiko
    Hatano, Satoko
    Asaka, Reimi
    Okumura, Sakae
    Nakagawa, Ken
    Mano, Hiroyuki
    Ishikawa, Yuichi
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3341 - 3348
  • [34] Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor
    Wang, Xiaoke
    Krishnan, Chandra
    Nguyen, Edward P.
    Meyer, Kevin J.
    Oliveira, Jennifer L.
    Yang, Ping
    Yi, Eunhee S.
    Erickson-Johnson, Michele R.
    Yaszemski, Michael J.
    Maran, Avudaiappan
    Oliveira, Andre M.
    HUMAN PATHOLOGY, 2012, 43 (11) : 2047 - 2052
  • [35] Pulmonary Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene
    Sokai, Akihiko
    Enaka, Makiko
    Sokai, Risa
    Mori, Shoichi
    Mori, Shunsuke
    Gunji, Masaharu
    Fujino, Masahiko
    Ito, Masafumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (01) : 93 - 96
  • [36] Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor
    Kaino, Akira
    Niizuma, Hidetaka
    Katayama, Saori
    Irie, Masahiro
    Nakano, Tomohiro
    Sato, Daichi
    Saito, Tsuyoshi
    Kato, Shunsuke
    Suehara, Yoshiyuki
    Sasahara, Yoji
    Kikuchi, Atsuo
    PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
  • [37] STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Vivek Subbiah
    Caitlin McMahon
    Shreyaskumar Patel
    Ralph Zinner
    Elvio G Silva
    Julia A. Elvin
    Ishwaria M. Subbiah
    Chimela Ohaji
    Dhakshina Moorthy Ganeshan
    Deepa Anand
    Charles F. Levenback
    Jenny Berry
    Tim Brennan
    Juliann Chmielecki
    Zachary R. Chalmers
    John Mayfield
    Vincent A. Miller
    Philip J. Stephens
    Jeffrey S. Ross
    Siraj M. Ali
    Journal of Hematology & Oncology, 8
  • [38] STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Subbiah, Vivek
    McMahon, Caitlin
    Patel, Shreyaskumar
    Zinner, Ralph
    Silva, Elvio G.
    Elvin, Julia A.
    Subbiah, Ishwaria M.
    Ohaji, Chimela
    Ganeshan, Dhakshina Moorthy
    Anand, Deepa
    Levenback, Charles F.
    Berry, Jenny
    Brennan, Tim
    Chmielecki, Juliann
    Chalmers, Zachary R.
    Mayfield, John
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Ali, Siraj M.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [39] Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report
    Zarei, Shabnam
    Abdul-Karim, Fadi W.
    Chase, Dana M.
    Astbury, Caroline
    Policarpio-Nicolas, Maria Luisa C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (02) : 152 - 156
  • [40] Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion
    Bennett, Jennifer A.
    Wang, Peng
    Wanjari, Pankhuri
    Diaz, Lidia
    Oliva, Esther
    GENES CHROMOSOMES & CANCER, 2021, 60 (12) : 822 - 826